+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 241 Pages
  • April 2024
  • Region: Global
  • Grand View Research
  • ID: 5967398
Description Jump to:

Small Molecule Innovator API CDMO Market Growth & Trends

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.53% from 2024 to 2030. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

Small Molecule Innovator API CDMO Market Report Highlights

  • The clinical stage type segment dominated the market with a share of 54.68% in 2023. Growth in the segment can be attributed to the rising clinical trial (phase I-III) activities for diverse formulations, growing small molecule development pipeline, increasing availability of specialized expertise, timesaving & cost-efficiency for investigational drugs, and innovations. Moreover, rising funding for drug development is propelling segment growth
  • Based on the customer type, the pharmaceutical segment held the largest share in 2023 due to rapid advancements in pharmaceutical R&D for the development of advanced drugs. In addition, advancements in various therapies have shifted pharmaceutical companies' focus on CDMOs to developing novel small molecule innovator API drugs to treat numerous diseases
  • The oncology therapeutic area segment dominated the market and accounted for a share of 42.25% in 2023. The segment growth is driven by the increasing prevalence of cancer globally. In addition, growing demand for innovative small molecule innovator APIs, advancements in targeted therapies, and demand for oncology drugs innovations are the factors driving the oncology segment
  • Asia Pacific dominated the market with a share of 41.53% in 2023 due to increasing prevalence of chronic diseases, demand for small molecule APIs & CDMO services, and improving healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
1.10.1. Objective - 1
1.10.2. Objective - 2
1.10.3. Objective - 3
1.10.4. Objective - 4
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary Market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Demand for Small Molecule Drugs
3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
3.2.1.3. Surge in Number of Clinical Trials
3.2.2. Market restraint analysis
3.2.2.1. Compliance Issues While Outsourcing
3.2.2.2. Changing Scenarios in Developing Economies
3.3. Technology Landscape
3.3.1. Integration Of Ai In Small Molecule Innovator API CDMO Market
3.3.1.1. Current Dynamics and Future Trends
3.3.1.1.1. Drug Discovery and Design
3.3.1.1.2. AI-Assisted Drug API Synthesis
3.3.1.1.3. Process Optimization
3.3.1.1.4. Supply Chain Management
3.3.1.1.5. Clinical Trial Optimization
3.3.1.1.6. Regulatory Compliance
3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
3.4.1. Total Number of Clinical Trials by Phase (2021 - 2023)
3.4.2. Total Number of Clinical Trials by Region (2021 - 2023)
3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
3.4.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
3.5. Small Molecule Innovator API CDMO Market: Analysis Tools
3.5.1. Porter's Five Forces Analysis
3.5.2. PESTEL Analysis
3.6. Impact of COVID-19 on Small Molecule Innovator CDMO Market
3.7. COVID-19 Impact Analysis
Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
4.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
4.3.1. Preclinical
4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2. Clinical
4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.2. Phase I
4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.3. Phase II
4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.4. Phase III
4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.3. Commercial
4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
5.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
5.3.1. Pharmaceutical
5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.2. Small
5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.3. Medium
5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.4. Large
5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2. Biotechnology
5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.2. Small
5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.3. Medium
5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.4. Large
5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Cardiovascular Diseases
6.1.2. Oncology
6.1.3. Respiratory Disorders
6.1.4. Neurology
6.1.5. Metabolic Disorders
6.1.6. Infectious Diseases
6.1.7. Others
6.2. Therapeutic Area Market Share, 2023 & 2030
6.3. Segment Dashboard
6.4. Global Small Molecule Innovator API CDMO Market Movement Analysis
6.5. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
6.5.1. Cardiovascular Diseases
6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.2. Oncology
6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.3. Respiratory Disorders
6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.4. Neurology
6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.5. Metabolic Disorders
6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.6. Infectious Diseases
6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.7. Others
6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Scenario
7.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Scenario
7.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Scenario
7.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Scenario
7.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Scenario
7.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Scenario
7.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Scenario
7.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Scenario
7.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Scenario
7.5.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Scenario
7.5.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Scenario
7.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3. Japan
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Scenario
7.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Scenario
7.6.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Scenario
7.6.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Scenario
7.6.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Scenario
7.6.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.8. Taiwan
7.6.8.1. Key Country Dynamics
7.6.8.2. Competitive Scenario
7.6.8.3. Regulatory Scenario
7.6.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Scenario
7.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.3. Mexico
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Scenario
7.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.4. Argentina
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Scenario
7.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Scenario
7.8.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Scenario
7.8.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Scenario
7.8.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Scenario
7.8.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.6. Israel
7.8.6.1. Key Country Dynamics
7.8.6.2. Competitive Scenario
7.8.6.3. Regulatory Scenario
7.8.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Service Heat Map Analysis (a comparative analysis of the players together)
8.3. Company Profiles
8.4. Company Profiles
8.4.1. Strategy Mapping
8.4.2. Expansion
8.4.3. Partnerships
8.4.4. Acquisitions
8.5. Vendor Landscape
8.5.1. Key company market share analysis, 2023
8.5.2. Lonza Group Ltd.
8.5.2.1. Company overview
8.5.2.2. Financial performance
8.5.2.3. Product/service benchmarking
8.5.2.4. Strategic initiatives
8.5.3. Novo Holdings (Catalent, Inc.)
8.5.3.1. Company overview
8.5.3.2. Financial performance
8.5.3.3. Product/service benchmarking
8.5.3.4. Strategic initiatives
8.5.4. Thermo Fisher Scientific, Inc.
8.5.4.1. Company overview
8.5.4.2. Financial performance
8.5.4.3. Product/service benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Siegfried Holding AG
8.5.5.1. Company overview
8.5.5.2. Financial performance
8.5.5.3. Product/service benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Recipharm AB
8.5.6.1. Company overview
8.5.6.2. Financial performance
8.5.6.3. Product/service benchmarking
8.5.6.4. Strategic initiatives
8.5.7. CordenPharma International
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product/service benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Samsung Biologics
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product/service benchmarking
8.5.8.4. Strategic initiatives
8.5.9. Labcorp
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product/service benchmarking
8.5.9.4. Strategic initiatives
8.5.10. Ajinomoto Bio-Pharma Services
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Product/service benchmarking
8.5.10.4. Strategic initiatives
8.5.11. Piramal Pharma Solutions
8.5.11.1. Company overview
8.5.11.2. Financial performance
8.5.11.3. Product/service benchmarking
8.5.11.4. Strategic initiatives
8.5.12. Jubilant Life Sciences (Jubilant Biosys Limited)
8.5.12.1. Company overview
8.5.12.2. Financial performance
8.5.12.3. Product/service benchmarking
8.5.12.4. Strategic initiatives
8.5.13. WuXi AppTec Co., Ltd.
8.5.13.1. Company overview
8.5.13.2. Financial performance
8.5.13.3. Product/service benchmarking
8.5.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 3 North America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 4 North America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 5 North America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 6 U.S. Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 7 U.S. Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 8 U.S. Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 9 Canada Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 10 Canada Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 11 Canada Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 12 Europe Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 13 Europe Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 14 Europe Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 15 Europe Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 16 UK Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 17 UK Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 18 UK Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 19 Germany Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 20 Germany Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 21 Germany Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 22 France Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 23 France Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 24 France Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 25 Italy Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 26 Italy Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 27 Italy Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 28 Spain Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 29 Spain Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 30 Spain Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 31 Denmark Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 32 Denmark Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 33 Denmark Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 34 Sweden Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 35 Sweden Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 36 Sweden Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 37 Norway Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 38 Norway Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 39 Norway Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 44 China Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 45 China Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 46 China Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 47 Japan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 48 Japan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 49 Japan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 50 India Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 51 India Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 52 India Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 53 Australia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 54 Australia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 55 Australia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 56 South Korea Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 57 South Korea Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 58 South Korea Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 59 Thailand Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 60 Thailand Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 61 Thailand Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 62 Taiwan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 63 Taiwan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 64 Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 65 Latin America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 66 Latin America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 67 Latin America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 68 Latin America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 69 Brazil Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 70 Brazil Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 71 Brazil Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 72 Mexico Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 73 Mexico Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 74 Mexico Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 75 Argentina Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 76 Argentina Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 77 Argentina Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 78 MEA Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
Table 79 MEA Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 80 MEA Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 81 MEA Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 82 South Africa Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 83 South Africa Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 84 South Africa Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 88 UAE Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 89 UAE Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 90 UAE Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 91 Kuwait Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 92 Kuwait Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 93 Kuwait Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 94 Israel Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 95 Israel Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 96 Israel Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Small molecule innovator API CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market outlook, 2023(USD Million)
Fig. 16 Ancillary market outlook, 2023 (USD Million)
Fig. 17 Small molecule innovator API CDMO market dynamics
Fig. 18 FDA’s novel drug approvals in 2023
Fig. 19 Percentage of clinical trials by major countries in North America
Fig. 20 Percentage of clinical trials by major countries in Europe
Fig. 21 Percentage of clinical trials by major countries in Asia Pacific
Fig. 22 Percentage of clinical trials by major countries in Latin America
Fig. 23 Percentage of clinical trials by major countries in Middle East & Africa
Fig. 24 Porter’s five forces analysis
Fig. 25 Small molecule innovator API CDMO market: PESTEL analysis
Fig. 26 Small molecule innovator API CDMO market: Stage Type outlook and key takeaways
Fig. 27 Small molecule innovator API CDMO market: Stage type movement analysis
Fig. 28 Preclinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Clinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Phase I small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Phase II small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Phase III small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Commercial small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Small molecule innovator API CDMO market: Customer type outlook and key takeaways
Fig. 35 Small molecule innovator API CDMO market: Customer type movement analysis
Fig. 36 Pharmaceutical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Small pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Medium pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Large pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Biotechnology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Small biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Medium biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Large biotechnology customer in small molecule molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Small molecule innovator API CDMO market: Therapeutic area outlook and key takeaways
Fig. 45 Small molecule innovator API CDMO market: Therapeutic area movement analysis
Fig. 46 Cardiovascular diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Oncology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Respiratory disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Neurology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Metabolic disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Infectious diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Others small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Regional market: Key takeaways
Fig. 54 Regional outlook, 2023 & 2030
Fig. 55 Regional outlook, 2023 & 2030
Fig. 56 North America small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 U.S. small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Canada small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Key country dynamics
Fig. 63 UK small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Germany small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 France small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Italy small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Spain small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 Denmark small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 Sweden small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Norway small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 MEA small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 South Africa small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Saudi Arabia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Clinical trial authorization process UAE
Fig. 86 UAE small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 Regulatory framework: South Africa
Fig. 89 Kuwait small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 Israel small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Asia Pacific small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 China small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 Regulatory bodies in India involved in pharmaceutical regulations
Fig. 98 India small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 Key country dynamics
Fig. 100 Clinical trial authorization process in Japan
Fig. 101 Clinical research of medical products in Japan
Fig. 102 Japan small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Key country dynamics
Fig. 104 Australia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 105 Key country dynamics
Fig. 106 Clinical trial approval process in South Korea
Fig. 107 South Korea small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 Key country dynamics
Fig. 109 Thailand small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Key country dynamics
Fig. 111 Taiwan small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 112 Rest of APAC small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 113 Key country dynamics
Fig. 114 Brazil small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 115 Key country dynamics
Fig. 116 Mexico small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 117 Key country dynamics
Fig. 118 Argentina pharmaceuticals registration details
Fig. 119 Argentina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 120 Market participant categorization
Fig. 121 Heat map analysis
Fig. 122 Market participant categorization

Companies Mentioned

  • Lonza Group Ltd.
  • Novo Holdings (Catalent, Inc.)
  • Thermo Fisher Scientific, Inc.
  • Siegfried Holding AG
  • Recipharm AB
  • CordenPharma International
  • Samsung Biologics
  • Labcorp
  • Ajinomoto Bio-Pharma Services
  • Piramal Pharma Solutions
  • Jubilant Life Sciences (Jubilant Biosys Limited)
  • WuXi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages241
PublishedApril 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 29.94 Billion
Forecasted Market Value ( USD ) by 2030 $ 47.14 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report by Product (Small Molecule API, Small Molecule Drug Product), Stage Type, Customer Type, Therapeutic Area, Region, and Segment Forecasts, 2024-2030 - Product Image

Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report by Product (Small Molecule API, Small Molecule Drug Product), Stage Type, Customer Type, Therapeutic Area, Region, and Segment Forecasts, 2024-2030

  • Report
  • 119 Pages
  • Global
From
Small Molecule Innovator API CDMO Market - Product Image

Small Molecule Innovator API CDMO Market

  • Report
  • 200 Pages
  • Global
From
Small Molecule Innovator CDMO Global Market Report 2024 - Product Image

Small Molecule Innovator CDMO Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Pharmaceutical CDMO Market Size, Share & Trends Analysis Report by Product (API, Drug Product), Workflow (Clinical, Commercial), Application (Oncology, Infectious Diseases, Neurological Disorders), Region, and Segment Forecasts, 2024-2030 - Product Image

Pharmaceutical CDMO Market Size, Share & Trends Analysis Report by Product (API, Drug Product), Workflow (Clinical, Commercial), Application (Oncology, Infectious Diseases, Neurological Disorders), Region, and Segment Forecasts, 2024-2030

  • Report
  • 342 Pages
  • Global
From
Small Molecule Innovator CDMO Market - Forecasts from 2024 to 2029 - Product Image

Small Molecule Innovator CDMO Market - Forecasts from 2024 to 2029

  • Report
  • 152 Pages
  • Global
From

About the Small Molecule Innovator API CDMO Market

In the pharmaceutical industry, the Small Molecule Innovator Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) market encompasses a network of companies that provide a wide array of services for the development, manufacturing, and commercialization of small molecule APIs. Small molecules, traditionally the cornerstone of pharmaceutical offerings, are organic compounds with low molecular weight that can easily enter cells and alter biological processes. The Small Molecule API CDMOs offer expertise in chemistry, helping innovator companies to accelerate the drug development pipeline from initial conception through clinical trials to market launch. These services are pivotal for pharmaceutical companies that lack the requisite infrastructure or choose to outsource these functions to focus on core competencies such as drug discovery and marketing. The CDMO market is characterized by its versatile array of technologies, including custom synthesis, process optimization, scale-up, and regulatory compliance designed to meet the bespoke needs of innovator companies. Several prominent companies are operating within the Small Molecule Innovator API CDMO market, including Catalent, Lonza Group, Patheon (part of Thermo Fisher Scientific), Siegfried Holding AG, Cambrex Corporation, Wuxi AppTec, and Piramal Pharma Solutions. These organizations have established reputations for their technical capabilities, compliance track records, and supply chain reliability, making them vital partners in the pharmaceutical manufacturing landscape. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.